Search Within

Smita Sarat Chandran

  1. "GSK Faculty"
Formats
  1. Journal Article (6)
  2. Meeting Abstract (5)
  3. Review (2)
  4. Editorial (1)
Groups
  1. Breast Medicine Service (14)
  2. Center for Molecular Imaging and Biotechnology (CMIB) (14)
  3. Department of Medicine (14)
  4. GSK Faculty (14)
  5. Hematologic Malignancies, Division of (14)
  6. Human Oncology and Pathogenesis Program (14)

More Groups

People
  1. Christopher Klebanoff (14)
  2. David Scheinberg (4)
  3. Martin Klatt (4)
  4. Hannah Wen (3)
  5. Inaki Etxeberria (3)
  6. Matthew Femia (3)

More People

Years
  1. 2025 (2)
  2. 2023 (1)
  3. 2022 (3)
  4. 2020 (3)
  5. 2019 (4)
  6. 2017 (1)
Publications
  1. Cancer Immunology Research (2)
  2. Journal for ImmunoTherapy of Cancer (2)
  3. Nature Medicine (2)
  4. Immunological Reviews (1)
  5. International Journal of Radiation Oncology, Biology, Physics (1)
  6. JCI Insight (1)

More Publications

Publishers
  1. Nature Publishing Group (5)
  2. American Association for Cancer Research (3)
  3. Biomed Central Ltd (2)
  4. Elsevier Inc. (2)
  5. Amer Soc Clinical Investigation Inc (1)
  6. Wiley Blackwell (1)

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enhancing the persistence and anti-tumor efficacy of CAR-T and CAR-NK cells through genetic disruption of death receptors
    Meeting Abstract

    Cohen, T. D.; Yi, F.; Zumbo, P.; Etilib, R.; Arkin, H.; Gormally, M.; Hackett, C. S.; Kropp, K.; Etxeberria, I.; Chandran, S. S.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Dynamic allostery in the peptide/MHC complex enables TCR neoantigen selectivity
    Journal Article

    Ma, J.; Ayres, C. M.; Brambley, C. A.; Chandran, S. S.; Rosales, T. J.; Gihan Perera, W. W. J.; Eldaly, B.; Murray, W. T.; Corcelli, S. A.; Kovrigin, E. L.; more...
    Nature Communications (2025)

    Fulltext@MSK | Save
  • T cell receptor therapeutics: Immunological targeting of the intracellular cancer proteome
    Review

    Klebanoff, C. A.; Chandran, S. S.; Baker, B. M.; Quezada, S. A.; Ribas, A.
    Nature Reviews Drug Discovery (2023)

    Fulltext@MSK | Save
  • Immunogenic landscape and therapeutic targeting of mutant NRAS "public" neoantigens
    Meeting Abstract

    Etxeberria, I.; Banks, L.; Chandran, S.; Correa, A.; Novak, B.; Fleischman, J.; Drilon, A.; Wolchok, J.; Merghoub, T.; Klebanoff, C.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • PIK3CA hotspot mutation generates a shared neoantigen targetable by TCR gene therapy
    Editorial

    Klebanoff, C. A.; Chandran, S. S.
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
    Journal Article

    Chandran, S. S.; Ma, J.; Klatt, M. G.; Dündar, F.; Bandlamudi, C.; Razavi, P.; Wen, H. Y.; Weigelt, B.; Zumbo, P.; Fu, S. N.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Elucidating the biologic basis of ER(+)/Her2(-) breast cancer tumors containing extensive tumor infiltrating lymphocytes through morphologic and genomic profiling
    Meeting Abstract

    Johnson, C. B.; Chandran, S. S.; Wen, H. Y.; Razavi, P.; Schietinger, A.; Klebanoff, C. A.
    International Journal of Radiation Oncology, Biology, Physics (2020)

    Fulltext@MSK | Save
  • Optimization of T-cell receptor-modified T cells for cancer therapy
    Journal Article

    Drakes, D. J.; Rafiq, S.; Purdon, T. J.; Lopez, A. V.; Chandran, S. S.; Klebanoff, C. A.; Brentjens, R. J.
    Cancer Immunology Research (2020)

    Fulltext@MSK | Save
  • Identification of the targets of T-cell receptor therapeutic agents and cells by use of a high-throughput genetic platform
    Journal Article

    Gejman, R. S.; Jones, H. F.; Klatt, M. G.; Chang, A. Y.; Oh, C. Y.; Chandran, S. S.; Korontsvit, T.; Zakahleva, V.; Dao, T.; Klebanoff, C. A.; more...
    Cancer Immunology Research (2020)

    Fulltext@MSK | Save
  • T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers
    Meeting Abstract

    Chandran, S.; Ma, J.; Klatt, M. G.; Dundar, F.; Zumbo, P.; Femia, M. R.; Betel, D.; Scheinberg, D. A.; Baker, B. M.; Klebanoff, C. A.
    Molecular Cancer Therapeutics (2019)

    Fulltext@MSK | Save